Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer

Titto A. Augustine, M. Baig, A. Sood, T. Budagov, G. Atzmon, J. M. Mariadason, S. Aparo, Radhashree Maitra, Sanjay Goel

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Telomeres are TTAGGG tandem repeats capping chromosomal ends and partially controlled by the telomerase enzyme. The EGFR pathway putatively regulates telomerase function, prompting an investigation of telomere length (TL) and its association with anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer (mCRC). Methods: Colorectal cancer cell lines were treated with multiple drugs and sensitivity determined. Clinical information was gathered from 75 patients who had received anti-EGFR drugs. Telomere length was measured using a validated qRT-PCR technique. Results: In CRC cell lines, TL independently predicted cetuximab sensitivity. Cells with shorter TL had growth inhibition of 18.6± 3.41% as compared with 41.39±8.58% in longer TL (P = 0.02). These in vitro findings were validated clinically, in a robust multivariate model. Among patients with KRas WT tumours, those with longer TL had a superior median progression-free survival (PFS) of 24.9 weeks than those with shorter TL; median 11.1 weeks, HR 0.31; P = 0.048. Conclusion: Telomere length could be a potential unique biomarker predictive of clinical benefit (PFS) of mCRC patients treated with anti-EGFR therapy. This is the novel demonstration of a complex hitherto undescribed interaction, placing anti-EGFR therapy, EGFR pathway, and the telomerase complex within a clinical context.

Original languageEnglish (US)
Pages (from-to)313-318
Number of pages6
JournalBritish Journal of Cancer
Volume112
Issue number2
DOIs
StatePublished - Jan 20 2015

Fingerprint

Telomere
Epidermal Growth Factor Receptor
Colorectal Neoplasms
Biomarkers
Telomerase
Therapeutics
Disease-Free Survival
Cell Line
Tandem Repeat Sequences
Pharmaceutical Preparations
Polymerase Chain Reaction
Enzymes
Growth

Keywords

  • Cetuximab
  • Epidermal growth factor receptor (EGFR)
  • Metastatic colorectal cancer
  • Panitumumab
  • Predictive biomarker
  • Telomere length

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer. / Augustine, Titto A.; Baig, M.; Sood, A.; Budagov, T.; Atzmon, G.; Mariadason, J. M.; Aparo, S.; Maitra, Radhashree; Goel, Sanjay.

In: British Journal of Cancer, Vol. 112, No. 2, 20.01.2015, p. 313-318.

Research output: Contribution to journalArticle

@article{b483fa0b96f64e17bff7636410e31862,
title = "Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer",
abstract = "Background: Telomeres are TTAGGG tandem repeats capping chromosomal ends and partially controlled by the telomerase enzyme. The EGFR pathway putatively regulates telomerase function, prompting an investigation of telomere length (TL) and its association with anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer (mCRC). Methods: Colorectal cancer cell lines were treated with multiple drugs and sensitivity determined. Clinical information was gathered from 75 patients who had received anti-EGFR drugs. Telomere length was measured using a validated qRT-PCR technique. Results: In CRC cell lines, TL independently predicted cetuximab sensitivity. Cells with shorter TL had growth inhibition of 18.6± 3.41{\%} as compared with 41.39±8.58{\%} in longer TL (P = 0.02). These in vitro findings were validated clinically, in a robust multivariate model. Among patients with KRas WT tumours, those with longer TL had a superior median progression-free survival (PFS) of 24.9 weeks than those with shorter TL; median 11.1 weeks, HR 0.31; P = 0.048. Conclusion: Telomere length could be a potential unique biomarker predictive of clinical benefit (PFS) of mCRC patients treated with anti-EGFR therapy. This is the novel demonstration of a complex hitherto undescribed interaction, placing anti-EGFR therapy, EGFR pathway, and the telomerase complex within a clinical context.",
keywords = "Cetuximab, Epidermal growth factor receptor (EGFR), Metastatic colorectal cancer, Panitumumab, Predictive biomarker, Telomere length",
author = "Augustine, {Titto A.} and M. Baig and A. Sood and T. Budagov and G. Atzmon and Mariadason, {J. M.} and S. Aparo and Radhashree Maitra and Sanjay Goel",
year = "2015",
month = "1",
day = "20",
doi = "10.1038/bjc.2014.561",
language = "English (US)",
volume = "112",
pages = "313--318",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer

AU - Augustine, Titto A.

AU - Baig, M.

AU - Sood, A.

AU - Budagov, T.

AU - Atzmon, G.

AU - Mariadason, J. M.

AU - Aparo, S.

AU - Maitra, Radhashree

AU - Goel, Sanjay

PY - 2015/1/20

Y1 - 2015/1/20

N2 - Background: Telomeres are TTAGGG tandem repeats capping chromosomal ends and partially controlled by the telomerase enzyme. The EGFR pathway putatively regulates telomerase function, prompting an investigation of telomere length (TL) and its association with anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer (mCRC). Methods: Colorectal cancer cell lines were treated with multiple drugs and sensitivity determined. Clinical information was gathered from 75 patients who had received anti-EGFR drugs. Telomere length was measured using a validated qRT-PCR technique. Results: In CRC cell lines, TL independently predicted cetuximab sensitivity. Cells with shorter TL had growth inhibition of 18.6± 3.41% as compared with 41.39±8.58% in longer TL (P = 0.02). These in vitro findings were validated clinically, in a robust multivariate model. Among patients with KRas WT tumours, those with longer TL had a superior median progression-free survival (PFS) of 24.9 weeks than those with shorter TL; median 11.1 weeks, HR 0.31; P = 0.048. Conclusion: Telomere length could be a potential unique biomarker predictive of clinical benefit (PFS) of mCRC patients treated with anti-EGFR therapy. This is the novel demonstration of a complex hitherto undescribed interaction, placing anti-EGFR therapy, EGFR pathway, and the telomerase complex within a clinical context.

AB - Background: Telomeres are TTAGGG tandem repeats capping chromosomal ends and partially controlled by the telomerase enzyme. The EGFR pathway putatively regulates telomerase function, prompting an investigation of telomere length (TL) and its association with anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer (mCRC). Methods: Colorectal cancer cell lines were treated with multiple drugs and sensitivity determined. Clinical information was gathered from 75 patients who had received anti-EGFR drugs. Telomere length was measured using a validated qRT-PCR technique. Results: In CRC cell lines, TL independently predicted cetuximab sensitivity. Cells with shorter TL had growth inhibition of 18.6± 3.41% as compared with 41.39±8.58% in longer TL (P = 0.02). These in vitro findings were validated clinically, in a robust multivariate model. Among patients with KRas WT tumours, those with longer TL had a superior median progression-free survival (PFS) of 24.9 weeks than those with shorter TL; median 11.1 weeks, HR 0.31; P = 0.048. Conclusion: Telomere length could be a potential unique biomarker predictive of clinical benefit (PFS) of mCRC patients treated with anti-EGFR therapy. This is the novel demonstration of a complex hitherto undescribed interaction, placing anti-EGFR therapy, EGFR pathway, and the telomerase complex within a clinical context.

KW - Cetuximab

KW - Epidermal growth factor receptor (EGFR)

KW - Metastatic colorectal cancer

KW - Panitumumab

KW - Predictive biomarker

KW - Telomere length

UR - http://www.scopus.com/inward/record.url?scp=84922337419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922337419&partnerID=8YFLogxK

U2 - 10.1038/bjc.2014.561

DO - 10.1038/bjc.2014.561

M3 - Article

C2 - 25412235

AN - SCOPUS:84922337419

VL - 112

SP - 313

EP - 318

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -